LUC00046I2 - - Google Patents

Download PDF

Info

Publication number
LUC00046I2
LUC00046I2 LU00046C LUC00046C LUC00046I2 LU C00046 I2 LUC00046 I2 LU C00046I2 LU 00046 C LU00046 C LU 00046C LU C00046 C LUC00046 C LU C00046C LU C00046 I2 LUC00046 I2 LU C00046I2
Authority
LU
Luxembourg
Application number
LU00046C
Original Assignee
Cold Spring Harbor Laboratory
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory, Biogen Ma Inc filed Critical Cold Spring Harbor Laboratory
Publication of LUC00046I1 publication Critical patent/LUC00046I1/fr
Publication of LUC00046I2 publication Critical patent/LUC00046I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU00046C 2005-06-23 2017-11-07 LUC00046I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69354205P 2005-06-23 2005-06-23
EP06773838A EP1910395B1 (fr) 2005-06-23 2006-06-23 Compositions et procédés de modulation de l épissage de SMN2

Publications (2)

Publication Number Publication Date
LUC00046I1 LUC00046I1 (fr) 2017-11-10
LUC00046I2 true LUC00046I2 (fr) 2018-01-10

Family

ID=37595872

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00046C LUC00046I2 (fr) 2005-06-23 2017-11-07

Country Status (13)

Country Link
US (6) US8361977B2 (fr)
EP (5) EP3470072A1 (fr)
CY (2) CY2017040I1 (fr)
DK (3) DK3308788T3 (fr)
ES (3) ES2702531T3 (fr)
HK (1) HK1247103B (fr)
HU (2) HUE027486T2 (fr)
LT (2) LT3308788T (fr)
LU (1) LUC00046I2 (fr)
PL (3) PL1910395T3 (fr)
PT (3) PT1910395E (fr)
SI (2) SI2548560T1 (fr)
WO (1) WO2007002390A2 (fr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
EP1855694B1 (fr) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Composition antisens permettant de traiter une atrophie musculaire
EP3470072A1 (fr) 2005-06-23 2019-04-17 Biogen MA Inc. Compositions et procédés pour modulation de l'épissage du smn2
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
WO2009064920A2 (fr) 2007-11-13 2009-05-22 Isis Pharmaceuticals, Inc. Composés et procédés pour moduler l'expression d'une protéine
WO2009151546A2 (fr) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Procédés de traitement d'une atrophie musculaire spinale
WO2010019243A1 (fr) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc. Méthodes de traitement d’infections virales
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
IT1398361B1 (it) * 2009-01-21 2013-02-22 Fond Santa Lucia Uso di mutanti dominanti negativi di sam68 per il trattamento della sma
CA2758189C (fr) * 2009-04-10 2020-12-29 Association Institut De Myologie Oligonucleotides antisens tricyclo-adn, compositions, et methodes de traitement de maladies
WO2010120820A1 (fr) * 2009-04-13 2010-10-21 Isis Pharmaceuticals, Inc. Compositions et procédés pour moduler l'épissage de smn2
ES2699827T3 (es) * 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
US8802642B2 (en) 2010-04-28 2014-08-12 Iowa State University Research Foundation, Inc. Spinal muscular atrophy treatment via targeting SMN2 catalytic core
KR20200133284A (ko) 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
US9518259B2 (en) * 2010-06-15 2016-12-13 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating interaction between proteins and target nucleic acids
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
IT1405793B1 (it) * 2010-10-15 2014-01-24 Univ Ferrara Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica
CA2817256A1 (fr) 2010-11-12 2012-05-18 The General Hospital Corporation Arn non codants associes a polycomb
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012138487A2 (fr) * 2011-04-07 2012-10-11 The Board Of Regents Of The University Of Texas System Modulation oligonucléotidique de l'épissage
CA3092114A1 (fr) 2011-05-05 2012-11-08 Sarepta Therapeutics, Inc. Conjugues peptides/oligonucleotides
WO2012178122A2 (fr) * 2011-06-23 2012-12-27 Cold Spring Harbor Laboratory Modèle phénocopique de maladie
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
WO2013068441A1 (fr) 2011-11-11 2013-05-16 Santaris Pharma A/S Composés pour la modulation de l'épissage de smn2
HK1201514A1 (en) 2011-11-18 2015-09-04 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
JP6496549B2 (ja) * 2011-11-30 2019-04-03 サレプタ セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症における誘発されたエクソン包含
US10066228B2 (en) 2011-11-30 2018-09-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
WO2013086207A1 (fr) * 2011-12-06 2013-06-13 The Ohio State University Agents de contraste non ioniques de faible osmolarité pour l'administration d'oligonucléotides antisens et le traitement de maladie
NZ627896A (en) 2012-01-27 2016-11-25 Biomarin Technologies B V Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
EA201492122A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии utrn
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
SG11201407483YA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating smn gene family expression
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
WO2014110291A1 (fr) * 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions et procédés pour la modulation de l'épissage de smn2 chez un sujet
WO2014113540A1 (fr) * 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. Cible intronique profonde pour la correction d'épissure sur le gène de l'amyotrophie spinale (sma)
US10590412B2 (en) 2013-04-19 2020-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
US11236338B2 (en) 2013-09-05 2022-02-01 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
WO2015051283A1 (fr) 2013-10-04 2015-04-09 Rana Therapeutics, Inc. Compositions et méthodes pour traiter la sclérose latérale amyotrophique (sla)
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
WO2015120450A1 (fr) * 2014-02-10 2015-08-13 Ohio State Innovation Foundation Oligonucléotides antisens dans le traitement de l'amyotrophie spinale
EP3797780B1 (fr) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions et procédés de modulation de l'épissage du smn2 chez un sujet
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
WO2016070060A1 (fr) 2014-10-30 2016-05-06 The General Hospital Corporation Procédés de modulation de la répression génique dépendant d'atrx
WO2016149455A2 (fr) 2015-03-17 2016-09-22 The General Hospital Corporation Interactome arn de complexe répressif polycomb 1 (prc1)
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
WO2016164896A2 (fr) 2015-04-10 2016-10-13 Ionis Pharmaceuticals, Inc. Modulation de l'expression de smn
MA50829A (fr) 2015-06-01 2018-04-11 Sarepta Therapeutics Inc Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
US10905709B2 (en) 2015-08-28 2021-02-02 Sarepta Therapeutics, Inc. Modified antisense oligomers for exon inclusion in spinal muscular atrophy
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
EP3858993A1 (fr) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions et procédés pour le traitement de la dystrophie musculaire de duchenne et de troubles apparentés
US9669109B1 (en) 2015-11-24 2017-06-06 Universita Di Ferrara Modified human U1snRNA molecule, a gene encoding for the modified human U1snRNA molecule, an expression vector including the gene, and the use thereof in gene therapy of familial dysautonomia and spinal muscular atrophy
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (fr) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Oligomères antisens destinés au traitement du retard mental dominant autosomique 5 et du syndrome de dravet
WO2017136435A1 (fr) 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Composés permettant de moduler l'expression de fc-epsilon-ri-bêta et utilisations correspondantes
WO2017184529A1 (fr) 2016-04-18 2017-10-26 Sarepta Therapeutics, Inc. Oligomères antisens et procédés d'utilisation de ceux-ci pour le traitement de maladies associées au gène de l'alpha-glucosidase acide
BR112018075667B1 (pt) 2016-06-14 2024-02-20 Biogen Ma, Inc Métodos para separar um oligonucleotídeo alvo de uma mistura contendo o oligonucleotídeo alvo e uma impureza relacionada com o produto
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
CN109689668B (zh) 2016-06-24 2023-02-17 比奥根Ma公司 无加帽步骤的硫醇化寡核苷酸的合成
EP3481432A4 (fr) 2016-07-05 2020-05-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Diagnostic de maladies associées au gène col6 et procédés de traitement associés
EP3485016A4 (fr) * 2016-07-15 2020-03-18 Ionis Pharmaceuticals, Inc. Composés et procédés de modulation du traitement de transcription
CA3043768A1 (fr) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes destines a l'administration d'agents therapeutiques
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
PT3589730T (pt) 2017-02-28 2024-02-28 Univ Pennsylvania Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
CA3060514A1 (fr) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions et procedes pour le traitement d'inflammation pulmonaire
US11549125B2 (en) 2017-08-09 2023-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereof
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
EP3694530A4 (fr) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. Compositions d'oligonucléotides et procédés associés
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
WO2019094253A1 (fr) 2017-11-08 2019-05-16 Avexis Inc. Moyens et procédé de préparation de vecteurs viraux et leurs utilisations
SG11202006528XA (en) 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN120310791A (zh) 2018-01-12 2025-07-15 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
CN119679944A (zh) 2018-01-25 2025-03-25 渤健马萨诸塞州股份有限公司 治疗脊髓性肌萎缩症的方法
CA3099280A1 (fr) * 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methodes et compositions pour le traitement d'une maladie de stockage d'ester de cholesteryle
EP3801638A1 (fr) 2018-06-08 2021-04-14 Novartis AG Dosage basé sur des cellules permettant de mesurer la puissance d'un produit médicamenteux
US20220089704A1 (en) 2018-10-29 2022-03-24 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
CN120860258A (zh) 2018-11-30 2025-10-31 北京诺华制药有限公司 Aav病毒载体及其用途
US12429487B2 (en) 2018-12-06 2025-09-30 Biogen Ma Inc. Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
US12595479B2 (en) 2019-03-20 2026-04-07 President And Fellows Of Harvard College Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
CN119143828A (zh) 2019-05-08 2024-12-17 渤健马萨诸塞州股份有限公司 寡核苷酸的汇聚液相合成
PT3999643T (pt) * 2019-07-19 2023-12-11 Biogen Ma Inc Métodos de tratamento da atrofia muscular espinhal
EP4058032A4 (fr) 2019-12-19 2024-01-10 Entrada Therapeutics, Inc. Compositions pour administrer des composés antisens
CN120505310A (zh) * 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
AU2022271873A1 (en) 2021-05-10 2024-01-04 Entrada Therapeutics, Inc. Compositions and methods for intracellular therapeutics
WO2023073526A1 (fr) 2021-10-25 2023-05-04 Novartis Ag Méthodes pour améliorer l'administration de virus adéno-associé (vaa)
FR3128873B1 (fr) 2021-11-10 2026-01-16 Biophytis Phytoecdysones et/ou dérivés de 20-hydroxyecdysone en combinaison avec un principe actif visant à restaurer l’expression SMN pour leur utilisation dans le traitement de l’amyotrophie spinale
WO2023240236A1 (fr) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale
IL326390A (en) 2023-08-10 2026-04-01 Univ Pennsylvania Compositions and methods for treating spinal muscular atrophy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
FR2645345A1 (fr) 1989-03-31 1990-10-05 Thomson Csf Procede de modulation dirigee de la composition ou du dopage de semi-conducteurs, notamment pour la realisation de composants electroniques monolithiques de type planar, utilisation et produits correspondants
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
DE69435005T2 (de) 1993-05-11 2008-04-17 The University Of North Carolina At Chapel Hill Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DE69527439T2 (de) 1994-02-28 2003-02-20 Agritech Technologies, Ltd. Inhibin enthaltende Zusammensetzung und ihre Verwendung
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
DE19906484A1 (de) * 1999-02-17 2000-09-07 Wegerer Kristina Elektrische Maschine
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6649411B2 (en) 1999-07-30 2003-11-18 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
US6770633B1 (en) 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
CA2437942C (fr) 2000-11-09 2013-06-11 Cold Spring Harbor Laboratory Molecules chimeres servant a moduler l'expression d'un gene
US6376508B1 (en) 2000-12-13 2002-04-23 Academia Sinica Treatments for spinal muscular atrophy
GB0219143D0 (en) 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2004113867A2 (fr) 2003-06-16 2004-12-29 University Of Massachusetts Analyse d'exon
GB0425625D0 (en) 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
EP3470072A1 (fr) 2005-06-23 2019-04-17 Biogen MA Inc. Compositions et procédés pour modulation de l'épissage du smn2
US20120021515A1 (en) 2009-02-06 2012-01-26 Swayze Eric E Oligomeric compounds and methods
WO2010120820A1 (fr) 2009-04-13 2010-10-21 Isis Pharmaceuticals, Inc. Compositions et procédés pour moduler l'épissage de smn2
ES2699827T3 (es) 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto

Also Published As

Publication number Publication date
ES2397113T3 (es) 2013-03-04
EP1910395A2 (fr) 2008-04-16
DK2548560T3 (en) 2015-07-13
DK3308788T3 (da) 2019-01-02
US20150353929A1 (en) 2015-12-10
LTPA2017037I1 (lt) 2017-11-27
US20170088835A1 (en) 2017-03-30
ES2545223T3 (es) 2015-09-09
US8946183B2 (en) 2015-02-03
EP1910395B1 (fr) 2012-10-17
US20100216238A1 (en) 2010-08-26
LT3308788T (lt) 2018-12-10
EP1910395A4 (fr) 2010-09-22
WO2007002390A3 (fr) 2007-11-15
HK1247103B (en) 2019-09-06
US20130109091A1 (en) 2013-05-02
LUC00046I1 (fr) 2017-11-10
SI2548560T1 (sl) 2015-12-31
EP3308788B1 (fr) 2018-10-24
EP3308788A1 (fr) 2018-04-18
HUE027486T2 (en) 2016-09-28
HK1181307A1 (en) 2013-11-08
US8361977B2 (en) 2013-01-29
EP3470072A1 (fr) 2019-04-17
CY2017040I2 (el) 2018-04-04
PL2548560T3 (pl) 2015-11-30
EP2548560B1 (fr) 2015-06-03
PT2548560E (pt) 2015-09-22
ES2702531T3 (es) 2019-03-01
EP2548560A1 (fr) 2013-01-23
EP2644700A1 (fr) 2013-10-02
PT3308788T (pt) 2019-01-30
PL1910395T3 (pl) 2013-03-29
PT1910395E (pt) 2012-12-03
CY1121134T1 (el) 2019-12-11
US20180291376A1 (en) 2018-10-11
LTC2548560I2 (lt) 2018-11-12
WO2007002390A2 (fr) 2007-01-04
SI3308788T1 (sl) 2019-01-31
DK1910395T3 (da) 2013-02-04
HUS1700042I1 (hu) 2017-12-28
US20200181613A1 (en) 2020-06-11
PL3308788T3 (pl) 2019-05-31
CY2017040I1 (el) 2018-04-04

Similar Documents

Publication Publication Date Title
BE2025C533I2 (fr)
BE2024C510I2 (fr)
BE2023C529I2 (fr)
BE2021C552I2 (fr)
BE2021C557I2 (fr)
BE2021C531I2 (fr)
BE2021C524I2 (fr)
BE2021C519I2 (fr)
BE2021C513I2 (fr)
BE2020C531I2 (fr)
BE2020C511I2 (fr)
BE2020C508I2 (fr)
BE2020C004I2 (fr)
BE2019C521I2 (fr)
BE2019C503I2 (fr)
BE2018C037I2 (fr)
BE2018C035I2 (fr)
BE2018C019I2 (fr)
BE2018C016I2 (fr)
BE2017C028I2 (fr)
BE2019C533I2 (fr)
BE2017C007I2 (fr)
BE2018C028I2 (fr)
BE2016C045I2 (fr)
BE2016C022I2 (fr)